Provided herein are compositions and methods for altering sensitivity of target cells to killing by γδ T cells.

Provided herein, inter alia, are compositions and methods including recombinant oncolytic viruses expressing CD47 antibody for the treatment of diseases including cancer, immune disorders, and infectious disease.

Provided herein, inter alia, are compositions and methods including recombinant oncolytic viruses expressing CD47 antibody for the treatment of diseases including cancer, immune disorders, and infectious disease.

Pan-coronavirus recombinant vaccine compositions featuring whole proteins or sequences of proteins encompassing all mutations in variants of human and animal Coronaviruses (e.g., 36 mutations in spike protein) or a combination of mutated B cell epitopes, mutated combination of B cell epitopes, mutated CD4+ T cell epitopes, and mutated CD8+ T cell epitopes, at least one of which is derived from a non-spike protein. The mutated epitopes may comprise one or more mutations. The present invention also describes using several immuno-informatics and sequence alignment approaches to identify several human B cell, CD4+ and CD8+ T cell epitopes that are highly mutated. The vaccine compositions herein have the potential to provide long-lasting B and T cell immunity regardless of human and animal Coronaviruses mutations.

Compositions and methods for treating a viral infection may comprise use of an adenoviral vector. An adenoviral vector of the present disclosure may comprise a non-human adenoviral genome with one or more gene locus functionally removed and a transgene. A method of treating a viral infection may comprise administering a composition comprising an adenoviral vector of the present disclosure, to a subject and reducing the infectivity or transmission of the virus. Intranasal administration provides enhance protection of the upper respiratory tract of a subject relative to intramuscular administration.

Compositions and methods for treating a viral infection may comprise use of an adenoviral vector. An adenoviral vector of the present disclosure may comprise a non-human adenoviral genome with one or more gene locus functionally removed and a transgene. A method of treating a viral infection may comprise administering a composition comprising an adenoviral vector of the present disclosure, to a subject and reducing the infectivity or transmission of the virus. Intranasal administration provides enhance protection of the upper respiratory tract of a subject relative to intramuscular administration.

Provided are T cell receptors that recognize or bind to Epstein-Barr virus (EBV) antigens, genetically engineered cells, and cell-based therapies.

The present invention is in the field of immunotherapy, in particular tumor immunotherapy. The present invention provides pharmaceutical formulations for delivering RNA to antigen presenting cells such as dendrite cells (DCs) in the spleen after systemic administration. In particular, the formulations described herein enable to induce an immune response after systemic administration of antigen-coding RNA.

The present inventors have found that innate immune response and T cell exhaustion pathway are more greatly over-expressed in pigs than cattle, such that the pigs are less likely to form adaptive and humoral immune responses than cattle. It would be suggested herein an innovative strategy for improvement of abnormal immune responses in pigs by simultaneously inducing potent cellular and humoral immune responses and applying T cell agonists as a new vaccine adjuvant. This result may provide an important clue for understanding a difference in the immune response between the cattle and pigs, while suggesting a method for maximizing the immune response and vaccine efficacy, which are less expressed in pigs than cattle.

The present inventors have found that innate immune response and T cell exhaustion pathway are more greatly over-expressed in pigs than cattle, such that the pigs are less likely to form adaptive and humoral immune responses than cattle. It would be suggested herein an innovative strategy for improvement of abnormal immune responses in pigs by simultaneously inducing potent cellular and humoral immune responses and applying T cell agonists as a new vaccine adjuvant. This result may provide an important clue for understanding a difference in the immune response between the cattle and pigs, while suggesting a method for maximizing the immune response and vaccine efficacy, which are less expressed in pigs than cattle.